AN2 Therapeutics, Inc. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
AN2 Therapeutics, Inc. (ANTX) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 7.70 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-11
- AN2 Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 7.72M shares, a 15.83% increase year-over-year.
- AN2 Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 6.66M shares, a 13.93% increase year-over-year.
- AN2 Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 5.85M shares, a 56.71% increase year-over-year.
- AN2 Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-03-31 was 3.73M shares, a 122.92% increase year-over-year.
- AN2 Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 6.35M shares, a 16.65% increase from fiscal 2024.
- AN2 Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 5.45M shares, a 27.48% increase from fiscal 2023.
- AN2 Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 4.27M shares, a 51.72% increase from fiscal 2022.
- AN2 Therapeutics, Inc. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 2.82M shares, a 78.45% decline from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 7.70M shares 10-Q · filed 2026-08-11 | |||||||
| 2026-03-31 | 7.72M shares 10-Q · filed 2026-05-11 | |||||||
| 2025-12-31 | 6.35M shares 10-K · filed 2026-03-17 | |||||||
| 2025-09-30 | 7.30M shares 10-Q · filed 2025-11-12 | |||||||
| 2025-06-30 | 6.85M shares 10-Q · filed 2026-08-11 | 7.64M shares 10-Q · filed 2025-08-12 | ||||||
| 2025-03-31 | 6.66M shares 10-Q · filed 2026-05-11 | 7.48M shares 10-Q · filed 2025-05-13 | ||||||
| 2024-12-31 | 5.45M shares 10-K · filed 2026-03-17 | 5.97M shares 10-K · filed 2025-03-25 | ||||||
| 2024-09-30 | 5.88M shares 10-Q · filed 2025-11-12 | 5.32M shares 10-Q · filed 2024-11-13 | ||||||
| 2024-06-30 | 6.55M shares 10-Q · filed 2025-08-12 | 5.96M shares 10-Q · filed 2024-08-13 | ||||||
| 2024-03-31 | 5.85M shares 10-Q · filed 2025-05-13 | 5.26M shares 10-Q · filed 2024-05-14 | ||||||
| 2023-12-31 | 4.27M shares 10-K · filed 2025-03-25 | 3.94M shares 10-K · filed 2024-03-29 | ||||||
| 2023-09-30 | 3.83M shares 10-Q · filed 2024-11-13 | |||||||
| 2023-06-30 | 3.90M shares 10-Q · filed 2024-08-13 | |||||||
| 2023-03-31 | 3.73M shares 10-Q · filed 2024-05-14 | |||||||
| 2022-12-31 | 2.82M shares 10-K · filed 2024-03-29 | |||||||
| 2022-09-30 | 2.49M shares 10-Q · filed 2023-11-09 | |||||||
| 2022-06-30 | 2.50M shares 10-Q · filed 2023-08-10 | |||||||
| 2022-03-31 | 1.67M shares 10-Q · filed 2023-05-11 | |||||||
| 2021-12-31 | 13.07M shares 10-K · filed 2023-03-29 | |||||||
| 2021-09-30 | 12.88M shares 10-Q · filed 2022-11-09 | |||||||
| 2021-06-30 | 12.57M shares 10-Q · filed 2022-08-11 | |||||||
| 2021-03-31 | 11.79M shares 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |